{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,15]],"date-time":"2026-07-15T15:36:11Z","timestamp":1784129771477,"version":"3.55.0"},"reference-count":22,"publisher":"Walter de Gruyter GmbH","issue":"9","license":[{"start":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T00:00:00Z","timestamp":1563494400000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2019,8,27]]},"abstract":"<jats:title>Abstract<\/jats:title>\n               <jats:sec id=\"j_cclm-2018-1228_s_999_w2aab3b7c53b1b6b1aab1c16b1Aa\">\n                  <jats:title>Background<\/jats:title>\n                  <jats:p>For pregnant women with suspected preeclampsia, the soluble fms-like tyrosine-kinase 1 (sFlt-1)\/placental growth factor (PlGF) ratio is a biomarker to aid diagnosis. We performed method comparisons between Elecsys<jats:sup>\u00ae<\/jats:sup> and Kryptor sFlt-1 and PlGF immunoassays and assessed the diagnostic performance for preeclampsia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2018-1228_s_998_w2aab3b7c53b1b6b1aab1c16b2Aa\">\n                  <jats:title>Methods<\/jats:title>\n                  <jats:p>Serum samples from a case-control study involving 113 pregnant women with preeclampsia\/elevated liver enzymes and low platelet count (HELLP) and 270 controls were analyzed. sFlt-1 and PlGF were measured using Roche Elecsys<jats:sup>\u00ae<\/jats:sup> and BRAHMS Kryptor sFlt-1\/PlGF immunoassays. The sFlt-1\/PlGF ratios were calculated, and Passing-Bablok regression\/Bland-Altman plots were performed. Gestation-specific cut-offs, \u226433 and \u226585\/\u2265110, were assessed.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2018-1228_s_997_w2aab3b7c53b1b6b1aab1c16b3Aa\">\n                  <jats:title>Results<\/jats:title>\n                  <jats:p>Mean (\u00b12 standard deviation [SD]) differences between the Elecsys<jats:sup>\u00ae<\/jats:sup> and Kryptor values were: sFlt-1, 173.13 pg\/mL (6237.66, \u22125891.40); PlGF, \u2212102.71 pg\/mL (186.06, \u2212391.48); and sFlt-1\/PlGF, 151.74 (1085.11, \u2212781.63). The Elecsys<jats:sup>\u00ae<\/jats:sup> and Kryptor immunoassays showed high correlation: Pearson\u2019s correlation coefficients were 0.913 (sFlt-1) and 0.945 (PlGF). Slopes were 1.06 (sFlt-1) and 0.79 (PlGF), resulting in ~20% lower values for Kryptor PlGF. Sensitivities and specificities using the sFlt-1\/PlGF \u226585 cut-off for early-onset preeclampsia (20\u2009+\u20090 to 33\u2009+\u20096 weeks) were 88.1%\/100.0% (Elecsys<jats:sup>\u00ae<\/jats:sup>) and 90.5%\/96.2% (Kryptor), respectively, and using the \u2265110 cut-off for late-onset preeclampsia (\u226534\u2009+\u20090 weeks) were 51.3%\/96.5% (Elecsys<jats:sup>\u00ae<\/jats:sup>) and 78.9%\/90.1% (Kryptor), respectively. Using Elecsys<jats:sup>\u00ae<\/jats:sup> and Kryptor sFlt-1\/PlGF, 0% and 3.8% of women, respectively, were falsely ruled-in for early-onset, and 3.5% and 9.9%, respectively, for late-onset preeclampsia.<\/jats:p>\n               <\/jats:sec>\n               <jats:sec id=\"j_cclm-2018-1228_s_996_w2aab3b7c53b1b6b1aab1c16b4Aa\">\n                  <jats:title>Conclusions<\/jats:title>\n                  <jats:p>Despite high correlation between the Elecsys<jats:sup>\u00ae<\/jats:sup> and Kryptor immunoassays, we observed significant differences between sFlt-1\/PlGF and PlGF results. Therefore, sFlt-1\/PlGF cut-offs validated for Elecsys<jats:sup>\u00ae<\/jats:sup> immunoassays are not transferable to Kryptor immunoassays.<\/jats:p>\n               <\/jats:sec>","DOI":"10.1515\/cclm-2018-1228","type":"journal-article","created":{"date-parts":[[2019,7,19]],"date-time":"2019-07-19T09:03:22Z","timestamp":1563527002000},"page":"1339-1348","source":"Crossref","is-referenced-by-count":29,"title":["Elecsys<sup>\u00ae<\/sup> and Kryptor immunoassays for the measurement of sFlt-1 and PlGF to aid preeclampsia diagnosis: are they comparable?"],"prefix":"10.1515","volume":"57","author":[{"given":"Holger","family":"Stepan","sequence":"first","affiliation":[{"name":"Department of Obstetrics , University of Leipzig , Liebigstr. 20a, 04103 , Leipzig , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Martin","family":"Hund","sequence":"additional","affiliation":[{"name":"Roche Diagnostics International Ltd , Rotkreuz , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Peter","family":"Dilba","sequence":"additional","affiliation":[{"name":"Roche Diagnostics GmbH , Penzberg , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Johanna","family":"Sillman","sequence":"additional","affiliation":[{"name":"Roche Diagnostics International Ltd , Rotkreuz , Switzerland"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Dietmar","family":"Schlembach","sequence":"additional","affiliation":[{"name":"Vivantes Network of Health, Clinicum Neukoelln, Clinic of Obstetrics , Berlin , Germany"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"374","published-online":{"date-parts":[[2019,7,19]]},"reference":[{"key":"2023033110071940286_j_cclm-2018-1228_ref_001_w2aab3b7c53b1b6b1ab2b1b1Aa","doi-asserted-by":"crossref","unstructured":"Duley L. The global impact of pre-eclampsia and eclampsia. Semin Perinatol 2009;33:130\u20137.","DOI":"10.1053\/j.semperi.2009.02.010"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_002_w2aab3b7c53b1b6b1ab2b1b2Aa","doi-asserted-by":"crossref","unstructured":"Ananth CV, Keyes KM, Wapner RJ. Pre-eclampsia rates in the United States, 1980\u20132010: age-period-cohort analysis. Br Med J 2013;347:f6564.","DOI":"10.1136\/bmj.f6564"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_003_w2aab3b7c53b1b6b1ab2b1b3Aa","doi-asserted-by":"crossref","unstructured":"Lain KY, Roberts JM. Contemporary concepts of the pathogenesis and management of preeclampsia. J Am Med Assoc 2002;287:3183\u20136.","DOI":"10.1001\/jama.287.24.3183"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_004_w2aab3b7c53b1b6b1ab2b1b4Aa","doi-asserted-by":"crossref","unstructured":"Young BC, Karumanchi SA. Toward a better diagnosis for preeclampsia. Clin Chem 2016;62:913\u20135.","DOI":"10.1373\/clinchem.2016.254920"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_005_w2aab3b7c53b1b6b1ab2b1b5Aa","doi-asserted-by":"crossref","unstructured":"Levine RJ, Lam C, Qian C, Yu KF, Maynard SE, Sachs BP, et al. Soluble endoglin and other circulating antiangiogenic factors in preeclampsia. N Engl J Med 2006;355:992\u20131005.","DOI":"10.1056\/NEJMoa055352"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_006_w2aab3b7c53b1b6b1ab2b1b6Aa","doi-asserted-by":"crossref","unstructured":"Verlohren S, Galindo A, Schlembach D, Zeisler H, Herraiz I, Moertl MG, et al. An automated method for the determination of the sFlt-1\/PIGF ratio in the assessment of preeclampsia. Am J Obstet Gynecol 2010;202:161.e1\u201311.","DOI":"10.1016\/j.ajog.2009.09.016"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_007_w2aab3b7c53b1b6b1ab2b1b7Aa","doi-asserted-by":"crossref","unstructured":"Herraiz I, Sim\u00f3n E, G\u00f3mez-Arriaga PI, Mart\u00ednez-Moratalla JM, Garc\u00eda-Burguillo A, Jim\u00e9nez EA, et al. Angiogenesis-related biomarkers (sFlt-1\/PLGF) in the prediction and diagnosis of placental dysfunction: an approach for clinical integration. Int J Mol Sci 2015;16:19009\u201326.","DOI":"10.3390\/ijms160819009"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_008_w2aab3b7c53b1b6b1ab2b1b8Aa","doi-asserted-by":"crossref","unstructured":"Sovio U, Gaccioli F, Cook E, Hund M, Charnock-Jones DS, Smith GC. Prediction of preeclampsia using the soluble fms-like tyrosine kinase 1 to placental growth factor ratio: a prospective cohort study of unselected nulliparous women. Hypertension 2017;69:731\u20138.","DOI":"10.1161\/HYPERTENSIONAHA.116.08620"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_009_w2aab3b7c53b1b6b1ab2b1b9Aa","doi-asserted-by":"crossref","unstructured":"Cerdeira AS, Agrawal S, Staff AC, Redman CW, Vatish M. Angiogenic factors: potential to change clinical practice in pre-eclampsia? Br J Obstet Gynaecol 2018;125:1389\u201395.","DOI":"10.1111\/1471-0528.15042"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_010_w2aab3b7c53b1b6b1ab2b1c10Aa","doi-asserted-by":"crossref","unstructured":"Verlohren S, Herraiz I, Lapaire O, Schlembach D, Zeisler H, Calda P, et al. New gestational phase-specific cutoff values for the use of the soluble fms-like tyrosine kinase-1\/placental growth factor ratio as a diagnostic test for preeclampsia. Hypertension 2014;63:346\u201352.","DOI":"10.1161\/HYPERTENSIONAHA.113.01787"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_011_w2aab3b7c53b1b6b1ab2b1c11Aa","doi-asserted-by":"crossref","unstructured":"Zeisler H, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. The sFlt-1\/PlGF ratio: ruling out pre-eclampsia for up to 4 weeks and the value of retesting. Ultrasound Obstet Gynecol 2019;53:367\u201375.","DOI":"10.1002\/uog.19178"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_012_w2aab3b7c53b1b6b1ab2b1c12Aa","doi-asserted-by":"crossref","unstructured":"Zeisler S, Llurba E, Chantraine F, Vatish M, Staff AC, Sennstrom M, et al. Predictive value of the sFlt-1:PlGF ratio in women with suspected preeclampsia. N Engl J Med 2016;374:13\u201322.","DOI":"10.1056\/NEJMoa1414838"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_013_w2aab3b7c53b1b6b1ab2b1c13Aa","doi-asserted-by":"crossref","unstructured":"Andersen LB, Frederiksen-M\u00f8ller B, Work Havelund K, Dechend R, J\u00f8rgensen JS, Jensen BL, et al. Diagnosis of preeclampsia with soluble Fms-like tyrosine kinase 1\/placental growth factor ratio: an inter-assay comparison. J Am Soc Hypertens 2015;2:86\u201396.","DOI":"10.1016\/j.jash.2014.11.008"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_014_w2aab3b7c53b1b6b1ab2b1c14Aa","doi-asserted-by":"crossref","unstructured":"van Helden J, Weiskirchen R. Analytical evaluation of the novel soluble fms-like tyrosine kinase 1 and placental growth factor assays for the diagnosis of preeclampsia. Clin Biochem 2015;48:1113\u20139.","DOI":"10.1016\/j.clinbiochem.2015.06.020"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_015_w2aab3b7c53b1b6b1ab2b1c15Aa","doi-asserted-by":"crossref","unstructured":"Dr\u00f6ge LA, H\u00f6ller A, Ehrlich L, Verlohren S, Henrich W, Perschel FH. Diagnosis of preeclampsia and fetal growth restriction with the sFlt-1\/PlGF ratio: diagnostic accuracy of the automated immunoassay Kryptor\u00ae. Pregnancy Hypertens 2017;8:31\u20136.","DOI":"10.1016\/j.preghy.2017.02.005"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_016_w2aab3b7c53b1b6b1ab2b1c16Aa","unstructured":"Roche Diagnostics. Method sheet Elecsys\u00ae PlGF. Mannheim, Germany, 2018."},{"key":"2023033110071940286_j_cclm-2018-1228_ref_017_w2aab3b7c53b1b6b1ab2b1c17Aa","unstructured":"Roche Diagnostics. Method sheet Elecsys\u00ae sFlt-1. Mannheim, Germany, 2018."},{"key":"2023033110071940286_j_cclm-2018-1228_ref_018_w2aab3b7c53b1b6b1ab2b1c18Aa","unstructured":"Thermo Fisher Scientific. Method sheet BRAHMS PlGF plus Kryptor. Hennigsdorf, Germany, 2015."},{"key":"2023033110071940286_j_cclm-2018-1228_ref_019_w2aab3b7c53b1b6b1ab2b1c19Aa","unstructured":"Thermo Fisher Scientific. Method sheet BRAHMS sFlt-1 Kryptor. Hennigsdorf, Germany, 2015."},{"key":"2023033110071940286_j_cclm-2018-1228_ref_020_w2aab3b7c53b1b6b1ab2b1c20Aa","unstructured":"Clinical and Laboratory Standards Institute (CLSI). Measurement procedure comparison and bias estimation using patient samples; approved guideline, 3rd ed. Document EP09-A3. Wayne, PA: CLSI, 2013."},{"key":"2023033110071940286_j_cclm-2018-1228_ref_021_w2aab3b7c53b1b6b1ab2b1c21Aa","doi-asserted-by":"crossref","unstructured":"Stepan H, Hund M, Gencay M, Denk B, Dinkel C,  Kaminski WE, et al. A comparison of the diagnostic utility of the sFlt-1\/PlGF ratio versus PlGF alone for the detection of preeclampsia\/HELLP syndrome. Hypertens Pregnancy 2016;35:295\u2013305.","DOI":"10.3109\/10641955.2016.1141214"},{"key":"2023033110071940286_j_cclm-2018-1228_ref_022_w2aab3b7c53b1b6b1ab2b1c22Aa","doi-asserted-by":"crossref","unstructured":"Law LW, Sahota DS, Chan LW, Chen M, Lau TK, Leung TY. Effect of long-term storage on placental growth factor and fms-like tyrosine kinase 1 measurements in samples from pregnant women. J Matern Fetal Neonatal Med 2010;23:1475\u201380.","DOI":"10.3109\/14767051003678242"}],"container-title":["Clinical Chemistry and Laboratory Medicine (CCLM)"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/www.degruyter.com\/view\/j\/cclm.2019.57.issue-9\/cclm-2018-1228\/cclm-2018-1228.xml","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2018-1228\/xml","content-type":"application\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2018-1228\/pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,3,31]],"date-time":"2023-03-31T11:10:45Z","timestamp":1680261045000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.degruyter.com\/document\/doi\/10.1515\/cclm-2018-1228\/html"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,7,19]]},"references-count":22,"journal-issue":{"issue":"9","published-online":{"date-parts":[[2019,4,5]]},"published-print":{"date-parts":[[2019,8,27]]}},"alternative-id":["10.1515\/cclm-2018-1228"],"URL":"https:\/\/doi.org\/10.1515\/cclm-2018-1228","relation":{},"ISSN":["1437-4331","1434-6621"],"issn-type":[{"value":"1437-4331","type":"electronic"},{"value":"1434-6621","type":"print"}],"subject":[],"published":{"date-parts":[[2019,7,19]]}}}